327 related articles for article (PubMed ID: 17062307)
21. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
Alper K; Schwartz KA; Kolts RL; Khan A
Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
[TBL] [Abstract][Full Text] [Related]
22. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
23. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
24. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
25. A refined symptom-based approach to diagnose pulmonary tuberculosis in children.
Marais BJ; Gie RP; Hesseling AC; Schaaf HS; Lombard C; Enarson DA; Beyers N
Pediatrics; 2006 Nov; 118(5):e1350-9. PubMed ID: 17079536
[TBL] [Abstract][Full Text] [Related]
26. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
27. FDA update.
Katz R
Epilepsy Res; 2006 Jan; 68(1):85-94. PubMed ID: 16377143
[TBL] [Abstract][Full Text] [Related]
28. Heat or eat: the Low Income Home Energy Assistance Program and nutritional and health risks among children less than 3 years of age.
Frank DA; Neault NB; Skalicky A; Cook JT; Wilson JD; Levenson S; Meyers AF; Heeren T; Cutts DB; Casey PH; Black MM; Berkowitz C
Pediatrics; 2006 Nov; 118(5):e1293-302. PubMed ID: 17079530
[TBL] [Abstract][Full Text] [Related]
29. Use of anesthetic agents in neonates and young children.
Mellon RD; Simone AF; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):509-20. PubMed ID: 17312200
[TBL] [Abstract][Full Text] [Related]
30. Changing requirements for evaluation of pharmacologic agents.
Chesney RW; Christensen ML
Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
[TBL] [Abstract][Full Text] [Related]
31. Off-label use of antiepileptic drugs for the treatment of neonatal seizures.
Silverstein FS; Ferriero DM
Pediatr Neurol; 2008 Aug; 39(2):77-9. PubMed ID: 18639748
[TBL] [Abstract][Full Text] [Related]
32. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications.
Kumar P; Walker JK; Hurt KM; Bennett KM; Grosshans N; Fotis MA
J Pediatr; 2008 Mar; 152(3):412-5. PubMed ID: 18280851
[TBL] [Abstract][Full Text] [Related]
33. Extemporaneous drug formulations.
Nahata MC; Allen LV
Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
[TBL] [Abstract][Full Text] [Related]
34. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
35. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
[TBL] [Abstract][Full Text] [Related]
36. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
37. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
38. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
39. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.
Fauchère JC; Dame C; Vonthein R; Koller B; Arri S; Wolf M; Bucher HU
Pediatrics; 2008 Aug; 122(2):375-82. PubMed ID: 18676556
[TBL] [Abstract][Full Text] [Related]
40. Neonatal seizures: treatment and treatment variability in 31 United States pediatric hospitals.
Blume HK; Garrison MM; Christakis DA
J Child Neurol; 2009 Feb; 24(2):148-54. PubMed ID: 19182150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
